Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040

被引：0
|
作者：
Sangro, Bruno [1 ,2 ]
He, Aiwu Ruth [3 ]
Yau, Thomas [4 ]
Hsu, Chiun [5 ]
Kang, Yoon-Koo [6 ,7 ]
Kim, Tae-You [8 ]
Santoro, Armando [9 ]
Melero, Ignacio [10 ]
Kudo, Masatoshi [11 ]
Ho, Ming-Mo [12 ]
Matilla, Ana [13 ,14 ]
Tovoli, Francesco [15 ]
Knox, Jennifer [16 ]
El-Rayes, Bassel [17 ]
Acosta, Mirelis Rivera [18 ]
Neely, Jaclyn [19 ]
Shen, Yun [19 ]
Tschaika, Marina [19 ]
El-Khoureiry, Anthony [20 ]
机构：
[1] Clin Univ Navarra, Pamplona, Spain
[2] CIBEREHD, Pamplona, Spain
[3] Georgetown Univ Hosp, Washington, DC 20007 USA
[4] Univ Hong Kong, Hong Kong, Peoples R China
[5] Natl Taiwan Univ Hosp, Taipei, Taiwan
[6] Asan Med Ctr, Seoul, South Korea
[7] Univ Ulsan, Seoul, South Korea
[8] Seoul Natl Univ, Seoul, South Korea
[9] Ist Clin Humanitas, Rozzano, Italy
[10] Univ Navarra, Pamplona, Spain
[11] Kindai Univ, Fac Med, Osaka, Japan
[12] Chang Gung Mem Hosp, Taipei, Taiwan
[13] Hosp Gen Univ Gregorio Maranon, Serv Digest, Madrid, Spain
[14] CIBEREHD, Madrid, Spain
[15] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
[16] Princess Margaret Canc Ctr, Toronto, ON, Canada
[17] Emory Univ, Winship Ctr, Atlanta, GA 30322 USA
[18] Fdn Invest, San Juan, PR USA
[19] Bristol Myers Squibb, Princeton, NJ USA
[20] USC, Norris Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LBO11
引用
收藏
页码：S121 / S122
页数：2
相关论文
共 50 条
  • [41] CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
    Kudo, Masatoshi
    Matilla, Ana
    Santoro, Armando
    Melero, Ignacio
    Gracian, Antonio Cubillo
    Acosta-Rivera, Mirelis
    Choo, Su-Pin
    El-Khoueiry, Anthony B.
    Kuromatsu, Ryoko
    El-Rayes, Bassel
    Numata, Kazushi
    Itoh, Yoshito
    Di Costanzo, Francesco
    Crysler, Oxana
    Reig, Maria
    Shen, Yun
    Neely, Jaclyn
    Tschaika, Marina
    Wisniewski, Tami
    Sangro, Bruno
    JOURNAL OF HEPATOLOGY, 2021, 75 (03) : 600 - 609
  • [42] Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.
    El-Khoueiry, Anthony B.
    Melero, Ignacio
    Yau, Thomas Cheung
    Crocenzi, Todd S.
    Kudo, Masatoshi
    Hsu, Chiun
    Choo, SuPin
    Trojan, Jorg
    Welling, Theodore
    Meyer, Tim
    Kang, Yoon-Koo
    Yeo, Winnie
    Chopra, Akhil
    Zhao, Huanyu
    Baakili, Adyb
    Dela Cruz, Christine Marie
    Sangro, Bruno
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [43] Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Burotto, Mauricio
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2022, 177 : 63 - 71
  • [44] 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO plus IPI) combination therapy in advanced melanoma
    Larkin, J. M. G.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. J.
    Rutkowski, P.
    Lao, C.
    Cowey, C. L.
    Schadendorf, D.
    Wagstaff, J.
    Dummer, R.
    Ferrucci, P. F.
    Smylie, M.
    Hogg, D.
    Hill, A.
    Marquez-Rodas, I.
    Haanen, J. B. A. G.
    Rizzo, J.
    Balogh, A.
    Hodi, F. S.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 904 - 905
  • [45] Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma
    Mika Takahashi
    Minika Takishita
    Yukako Yamazato
    Hiroaki Kakinoki
    Kazuma Udo
    Shohei Tobu
    Mitsuru Noguchi
    CEN Case Reports, 2023, 12 : 237 - 241
  • [46] Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2024, 13 (05) : 459 - 467
  • [47] Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma
    Takahashi, Mika
    Takishita, Minika
    Yamazato, Yukako
    Kakinoki, Hiroaki
    Udo, Kazuma
    Tobu, Shohei
    Noguchi, Mitsuru
    CEN CASE REPORTS, 2023, 12 (02) : 237 - 241
  • [48] Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial
    Motzer, Robert J.
    Russo, Paul
    Grunwald, Viktor
    Tomita, Yoshihiko
    Barthelemy, Philippe
    Goh, Jeffrey C.
    Cutuli, Hernan Javier
    Simsek, Burcin
    Spiridigliozzi, Julia
    Chudnovsky, Aleksander
    Bex, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
    Shirotake, Suguru
    Miyama, Y. U.
    Baba, Yasutaka
    Tajima, Hiroyuki
    Okada, Yoshitaka
    Nakazawa, Ken
    Usami, Yoko
    Yasuda, Masanori
    Igarashi, Daisuke
    Kaneko, G. O.
    Kanao, Kent
    Oyama, Masafumi
    Nishimoto, Koshiro
    ANTICANCER RESEARCH, 2022, 42 (05) : 2727 - 2735
  • [50] Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.
    Emamekhoo, Hamid
    Olsen, Mark R.
    Carthon, Bradley Curtis
    Drakaki, Alexandra
    Percent, Ivor John
    Molina, Ana M.
    Cho, Daniel C.
    Bendell, Johanna C.
    Gordan, Lucio N.
    Kalebasty, Arash Rezazadeh
    George, Daniel J.
    Hutson, Thomas E.
    Arrowsmith, Edward
    Zhang, Joshua
    Zoco, Jesus
    Johansen, Jennifer L.
    Leung, David
    Tykodi, Scott S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345